Medlab Clinical Share Price and Company Fundamentals
Last traded: Yesterday at 6:10 AM
Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia. Its lead drug candidate includes NanaBis, an oroÂbuccal administered equimolar tetrahydrocannabinol (THC) and cannabidiol (CBD) formulation as monotherapy, which is in phase 3 multi-centre, quadruple-blind, randomized- withdrawal active, and placebo-controlled clinical study for the management of opioid-requiringÂboneÂpain due to metastatic cancer. The company also develops NanoCelle, a patented sub-micron drug delivery platform that enhances drug solubility issues and enables faster absorption and metabolism of active ingredients. In addition, it offers vitamins and supplements; and virtual clinic services. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.
|Primary activities||Nutritional pharmaceutical research and development.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||Building A Unit A5 â A6, Botany Quarter 11-13 Lord Street Botany NSW 2019 Australia|
|Phone / Fax||61 2 8188 0311 / 61 2 9699 3347|
|Share registry||ADVANCED SHARE REGISTRY SERVICES|
Medlab Clinical does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Medlab Clinical.
|Dr. Sean Michael Hall||MD, CEO & Director||379.11k|
|Mr. Ian Curtinsmith||Chief Information Officer||71.2k|
|Dr. Luis Vitetta BSc(Hons), Grad Dip, Ph.D., Grad Dip Nutr||Director of Medical Research||304.07k|
|Dr. David A. Rutolo||Director of Science||192.44k|
|Mr. Kerem Kaya||CFO, COO & Company Sec.|
|Mr. Tony Potter||Director of Pharmaceuticals Sales, Marketing & Education|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Medlab Clinical is 53.04M and its enterprise value is 41.06M. The enterprise value to revenue ratio of MDC is 9.33.
The MDC's stocks Beta value is 1.22 making it 22% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Medlab Clinical (MDC)
Medlab Clinical (ASX:MDC) Frequently Asked Questions
1. What is Medlab Clinical's Stock Symbol?
Medlab Clinical trades on ASX under the ticker symbol "MDC".
2. What is Medlab Clinical's stock price today?
One share of MDC stock can currently be purchased for approximately $0.155.
3. How can I contact Medlab Clinical?
Medlab Clinical's mailing address is Building A Unit A5 â A6, Botany Quarter 11-13 Lord Street Botany NSW 2019 Australia. The company can be reached via phone at 61 2 8188 0311.
4. What is Medlab Clinical's official website?
The official website of Medlab Clinical is http://www.medlab.co.
5. Which share registry manages Medlab Clinical's stock?
Medlab Clinical's stock is managed by ADVANCED SHARE REGISTRY SERVICES.